In Phase 2, retatrutide produced mean weight loss of roughly 24% at 48 weeks at the highest dose, while tirzepatide achieved about 2022% in the SURMOUNT obesity trials cross-trial comparisons should be interpreted cautiously
Scotts Restorative Health is your trusted partner
Lifestyle changesadding resistance training, increasing protein intake, improving sleep, and addressing hidden calorie sourcescan restart progress without dose adjustment
What New Trials Suggest About Pain and Mobility May 11, 2026 Articles, Bone & Joint, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,309 views For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off
Tirzepatide engages both GLP-1 and GIP receptors, offering a different mechanism that can reignite weight loss when semaglutide alone has plateaued
Some healthcare providers may accept used Ozempic pens for disposal
